Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drugmetabolizing activity

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Xu, J ^a   Wang, J ^a   Hu, Y ^a   Qian, J ^a   Xu, B ^b   Chen, H ^a   Zou, W ^c   Fang, J Y ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cancer; CYP3A4; Gain of function; Mutation; P53; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; PROTEIN P53; RAPAMYCIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL RESPIRATION; GAIN OF FUNCTION MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 CYP3A; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; SURVIVAL ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84897432242     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.75     Document Type: Article

References (37)

1. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
2. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-263.
3. Xu J, Zhou X, Wang J, Li Z, Kong X, Qian J et al. RhoGAPs attenuate cell proliferation by direct interaction with p53 tetramerization domain. Cell Rep 2013; 3: 1526-1538.
4. Guo L, Liew HP, Camus S, Goh AM, Chee LL, Lunny DP et al. Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Oncogene 2013; 32: 4009-4016.
5. Endo A, Moyori A, Kobayashi A, Wong RW. Nuclear mitotic apparatus protein, NuMA, modulates p53-mediated transcription in cancer cells. Cell Death Dis 2013; 4: e713.
6. Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013; 493: 542-546.
7. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell biol 2013; 15: 2-8.
8. Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2010; 2: a000919.
9. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13: 994-1002.
10. Follis AV, Chipuk JE, Fisher JC, Yun MK, Grace CR, Nourse A et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat Chem Biol 2013; 9: 163-168.
11. Hagn F, Klein C, Demmer O, Marchenko N, Vaseva A, Moll UM et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem 2010; 285: 3439-3450.
12. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 1995; 11: 1389-1394.
13. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18: 1487-1499.
14. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013; 32: 1252-1265.
15. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
16. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
17. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 2013; 20: 898-909.
18. Wang W, Cheng B, Miao L, Mei Y, Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis 2013; 4: e574.
19. Paradiso A, Scarpi E, Malfettone A, Addati T, Giotta F, Simone G et al. Nuclear NHERF1 expression as a prognostic marker in breast cancer. Cell Death Dis 2013; 4: e904.
20. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 2003; 95: 961-970.
21. Vegran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PloS One 2013; 8: e55103.
22. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012; 14: R70.
23. Cancer Genome Atlas Research. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
24. Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
25. Cancer Genome Atlas Research. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
26. Cancer Genome Atlas Research. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
27. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum mutat 2007; 28: 622-629.
28. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-295.
29. Hanel W, Marchenko N, Xu S, Xiaofeng YuS, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 2013; 20: 898-909.
30. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
31. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
32. Xu J, Wang J, Xu B, Ge H, Zhou X, Fang JY. Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria. Mol Cancer Ther 2013; 12: 717-724.
33. Kong X, Qian J, Chen LS, Wang YC, Wang JL, Chen H et al. Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J Natl Cancer Inst 2013; 105: 1738-1749.
34. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013; 31: 3133-3140.
35. Braun R, Finney R, Yan C, Chen QR, Hu Y, Edmonson M et al. Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients. PLoS One 2013; 8: e55037.
36. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007; 23: 3251-3253.
37. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.